OncLive SOSS

Authors

Lan G. Coffman, MD, PhD

Latest:

Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression

Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer and high folate receptor-alpha expression.

Lana Hamieh, MD

Latest:

Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Lana Kandalaft, PharmD, PhD

Latest:

Dr. Kandalaft on an Ovarian Cancer Immunotherapy

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Latest:

Reduce Costs By Using Less Radiotherapy

Radiation therapy remains fertile for continued technological innovation that can improve patient outcomes, but of the newest technologies may be practical for only the largest institutions.

Lani Alison, BCN, MS, HCQ, PCMH, CCE

Latest:

Methods on Improving Survivorship and Palliative Care

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.

Lara Kujtan, MD

Latest:

Dr. Kujtan on Frontline Therapy for EGFR-Positive NSCLC

Lara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses frontline therapy for patients with EGFR-positive non–small cell lung cancer (NSCLC).

Larry Anderson, MD, PhD

Latest:

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Larry J. Copeland, MD

Latest:

Dr. Copeland on the Importance of Germline Testing in Ovarian Cancer

Larry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.

Larry Kestin MD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Lars Bastholt, MD

Latest:

Dr. Bastholt on Lenvatinib in Thyroid Cancer

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.

Latest:

A Life Redirected: Pursuing a Nursing Career After Osteosarcoma

In the summer of 2010, 20-year-old physical therapy student Hannah Komai was diagnosed with low-grade osteosarcoma after an incisional biopsy.

Laura C. Michaelis, MD

Latest:

Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AML

Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.

Laura Dawson, MD

Latest:

Dr Dawson on Palliative Radiotherapy in Symptomatic HCC or Liver Metastases

Laura Dawson, MD, FRCPC, discusses the investigation of palliative radiotherapy for patients with symptomatic hepatocellular carcinoma or liver metastases.

Laura Esserman, MD

Latest:

Dr. Esserman on Screening Patients With Higher-Risk DCIS

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.

Laura Esserman, MD, MBA

Latest:

Dr. Esserman on Personalized Screenings for Breast Cancer

Laura Esserman, MD, MBA, professor, University of California, San Francisco, discusses personalized versus annual screenings for breast cancer.

Laura J. Esserman, MD

Latest:

Dr. Esserman Discusses the I-SPY 2 Trial

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Laura J. Esserman, MD, MBA

Latest:

Dr. Esserman on the I-SPY2 Trial in Breast Cancer

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Laura L. Holman, MD

Latest:

Dr. Holman on Screening for Ovarian Cancer

Laura L. Holman, MD, discusses screening options for ovarian cancer.

Laura M. Freedman, MD

Latest:

Dr. Freedman on the NCCN Guidelines for Post-Mastectomy Radiation

Laura M. Freedman, MD, assistant professor, director of Radiation Oncology, Sylvester Comprehensive Cancer Center, discusses the revised National Comprehensive Cancer Network (NCCN) guidelines for post-mastectomy radiation given in women who have pathologic T1 and T2 tumors and 1 to 3 positive lymph nodes.